BRPI0916500A2 - cinco formas de cristal, métodos de preparação, composições farmacêuticas e aplicações de xlf-iii-43 - Google Patents

cinco formas de cristal, métodos de preparação, composições farmacêuticas e aplicações de xlf-iii-43

Info

Publication number
BRPI0916500A2
BRPI0916500A2 BRPI0916500A BRPI0916500A BRPI0916500A2 BR PI0916500 A2 BRPI0916500 A2 BR PI0916500A2 BR PI0916500 A BRPI0916500 A BR PI0916500A BR PI0916500 A BRPI0916500 A BR PI0916500A BR PI0916500 A2 BRPI0916500 A2 BR PI0916500A2
Authority
BR
Brazil
Prior art keywords
xlf
iii
applications
pharmaceutical compositions
preparation methods
Prior art date
Application number
BRPI0916500A
Other languages
English (en)
Inventor
Cheng Wang
Li Zhang
Ping Xie
Xiaoguang Chen
Yang Lv
Original Assignee
Inst Materia Medica Cams
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Materia Medica Cams filed Critical Inst Materia Medica Cams
Publication of BRPI0916500A2 publication Critical patent/BRPI0916500A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0916500A 2008-11-28 2009-11-28 cinco formas de cristal, métodos de preparação, composições farmacêuticas e aplicações de xlf-iii-43 BRPI0916500A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200810227626.0A CN101747305B (zh) 2008-11-28 2008-11-28 硝克柳胺化合物晶v型、其制法和其药物组合物与用途
PCT/CN2009/075196 WO2010060387A1 (zh) 2008-11-28 2009-11-28 硝克柳胺化合物五种晶型、其制法和其药物组合物与用途

Publications (1)

Publication Number Publication Date
BRPI0916500A2 true BRPI0916500A2 (pt) 2016-05-17

Family

ID=42225269

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0916500A BRPI0916500A2 (pt) 2008-11-28 2009-11-28 cinco formas de cristal, métodos de preparação, composições farmacêuticas e aplicações de xlf-iii-43

Country Status (10)

Country Link
US (1) US8729280B2 (pt)
EP (1) EP2361907A4 (pt)
JP (2) JP2012509909A (pt)
KR (1) KR101330063B1 (pt)
CN (5) CN101747305B (pt)
BR (1) BRPI0916500A2 (pt)
CA (1) CA2744828C (pt)
EA (1) EA024071B1 (pt)
IL (1) IL213177A0 (pt)
WO (1) WO2010060387A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101747305B (zh) * 2008-11-28 2014-06-18 中国医学科学院药物研究所 硝克柳胺化合物晶v型、其制法和其药物组合物与用途
SG191992A1 (en) 2011-01-19 2013-08-30 Univ Cincinnati Apolipoprotein aiv as an antidiabetic peptide
WO2013109342A1 (en) 2012-01-19 2013-07-25 University Of Cincinnati Method of treating diabetes using non-glycosylated apolipoprotein a-iv
US10232019B2 (en) 2012-07-25 2019-03-19 University Of Cincinnati Method of treating hyperglycemic disorders using apolipoprotein AIV
JP2015524808A (ja) 2012-07-25 2015-08-27 ユニバーシティ・オブ・シンシナティ アポリポタンパク質ａｉｖを用いたｉ型糖尿病の治療法
CN107868069A (zh) * 2017-10-31 2018-04-03 山东新华制药股份有限公司 7‑羟基‑8‑甲基‑6‑硝基‑2‑氧‑2h‑苯并吡喃‑3‑羧酸的制备工艺
CN107935976B (zh) * 2017-11-13 2020-01-17 山东大学 香豆素酰胺衍生物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2115409B (en) * 1982-02-24 1985-08-07 Zyma Sa Novel crystal modifications of (+)-catechin
SE510305C2 (sv) * 1997-05-30 1999-05-10 Astra Ab Nytt salt
CN1506359A (zh) 2002-12-05 2004-06-23 �й�ҽѧ��ѧԺҩ���о��� 新的香豆素酰胺衍生物及其制法和其药物组合物与用途
BRPI0508260A (pt) * 2004-03-02 2007-07-31 Takeda Pharmaceutical sal de metal alcalino terroso ou um sal de amina orgánico de um composto, composto, processo para a produção de um sal de metal alcalino terroso de um composto, cristal, medicamento, agente para a regressão, inibição da progressão ou estabilização de uma lesão arteriosclerótica ou aterosclerótica, uso do composto
CN101747305B (zh) * 2008-11-28 2014-06-18 中国医学科学院药物研究所 硝克柳胺化合物晶v型、其制法和其药物组合物与用途

Also Published As

Publication number Publication date
CN103833712A (zh) 2014-06-04
EA024071B1 (ru) 2016-08-31
CN101747305B (zh) 2014-06-18
US8729280B2 (en) 2014-05-20
CN103833713A (zh) 2014-06-04
JP2012509909A (ja) 2012-04-26
US20110319401A1 (en) 2011-12-29
EP2361907A4 (en) 2012-07-25
WO2010060387A1 (zh) 2010-06-03
KR101330063B1 (ko) 2013-11-18
CA2744828A1 (en) 2010-06-03
CN103833713B (zh) 2016-02-03
CN103833712B (zh) 2016-02-03
CN101896477B (zh) 2013-01-30
EP2361907A1 (en) 2011-08-31
KR20110114549A (ko) 2011-10-19
IL213177A0 (en) 2011-07-31
CN103788043A (zh) 2014-05-14
CN103788043B (zh) 2016-02-03
CN101747305A (zh) 2010-06-23
CN101896477A (zh) 2010-11-24
CA2744828C (en) 2015-05-05
JP6126040B2 (ja) 2017-05-10
JP2014141524A (ja) 2014-08-07
EA201100831A1 (ru) 2012-04-30

Similar Documents

Publication Publication Date Title
DK2475372T4 (da) Fremgangsmåde til fremstilling af micro-RNA og dets terapeutiske anvendelse
ES2769357T8 (es) Formas farmacéuticas de apixaban
DK2273975T3 (da) Farmaceutiske opløsninger, fremgangsmåde til fremstilling og terapeutiske anvendelser
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
CR10406A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
DK3795573T3 (da) Bestemte triazolopyraziner, sammensætninger deraf og fremgangsmåder til anvendelse deraf
BR112012022878A2 (pt) composto, composição farmacêutica, uso do compostos e método de tratamento
DK2297385T3 (da) Polymere sammensætninger, som omfatter polymælkesyre, og fremgangsmåder til fremstilling og anvendelse deraf
BRPI0908021A2 (pt) Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
BRPI0915680A2 (pt) miméticos de glicocorticoide, métodos de prepará-los, composições farmacêuticas, e usos dos mesmos
BRPI0914343A2 (pt) composição, produto, uso da composição e método
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
DK2643018T3 (da) Anti-il-6-antistoffer til behandling af oral mucositis
DK2178796T3 (da) Kontinuerlig fremgangsmåde til behandling af væsker og fremstilling af visse bestanddele
DK2729151T3 (da) Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf
BRPI1009372A2 (pt) compostos, composição farmacêutica e respectivos usos
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
BRPI0907077A2 (pt) métodos e composições para administração oral de proteínas
BR112012003842A2 (pt) composição farmacêutica, método de formulação e uso da mesma
DK3011975T3 (da) Faststofsammensætning til oral administration af farvestoffer og diagnostisk anvendelse deraf
BRPI0916500A2 (pt) cinco formas de cristal, métodos de preparação, composições farmacêuticas e aplicações de xlf-iii-43
FI20135146L (fi) Farmaseuttiset koostumukset ja hoitomenetelmät
DK2320740T3 (da) Farmaceutiske sammensætninger af clevidipin og fremgangsmåder tilfremstilling af koncentrationer deraf med lave urenhedsgrader
BR112012000831A2 (pt) compostos, composições farmacêuticas e métodos relacionados
DK2475649T3 (da) Indenonderivat og farmaceutisk sammensætning omfattende samme

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]